🇺🇸 FDA
Patent

US 9056087

Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives

granted A61KA61K2039/505A61K38/2292

Quick answer

US patent 9056087 (Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives) held by REGENERX BIOPHARMACEUTICALS, INC. expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERX BIOPHARMACEUTICALS, INC.
Grant date
Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K38/2292, A61P, A61P9/10